ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 132 filers reported holding ENANTA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.88 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $55,605 | -89.4% | 4,978 | -79.7% | 0.00% | – |
| Q2 2023 | $523,936 | -7.1% | 24,483 | +75.5% | 0.00% | – |
| Q1 2023 | $564,219 | +1386.4% | 13,952 | +1609.8% | 0.00% | – |
| Q4 2022 | $37,960 | -60.5% | 816 | -56.2% | 0.00% | – |
| Q3 2022 | $96,000 | -2.0% | 1,861 | -10.5% | 0.00% | – |
| Q2 2022 | $98,000 | -91.7% | 2,080 | -87.5% | 0.00% | – |
| Q1 2022 | $1,187,000 | -29.0% | 16,684 | -25.3% | 0.00% | – |
| Q4 2021 | $1,671,000 | +89.7% | 22,343 | +44.1% | 0.00% | – |
| Q3 2021 | $881,000 | -3.2% | 15,508 | -25.0% | 0.00% | – |
| Q2 2021 | $910,000 | +339.6% | 20,665 | +392.4% | 0.00% | – |
| Q1 2021 | $207,000 | -88.4% | 4,197 | -90.1% | 0.00% | – |
| Q4 2020 | $1,779,000 | -4.3% | 42,244 | +4.1% | 0.00% | -100.0% |
| Q3 2020 | $1,858,000 | -10.8% | 40,575 | -2.2% | 0.00% | 0.0% |
| Q2 2020 | $2,083,000 | +17.9% | 41,493 | +20.8% | 0.00% | 0.0% |
| Q1 2020 | $1,767,000 | -10.9% | 34,351 | +7.0% | 0.00% | 0.0% |
| Q4 2019 | $1,983,000 | +10.2% | 32,094 | +7.2% | 0.00% | 0.0% |
| Q3 2019 | $1,799,000 | -26.0% | 29,946 | +3.9% | 0.00% | 0.0% |
| Q2 2019 | $2,432,000 | -6.3% | 28,826 | +6.1% | 0.00% | 0.0% |
| Q1 2019 | $2,595,000 | +32.9% | 27,158 | -1.5% | 0.00% | 0.0% |
| Q4 2018 | $1,953,000 | -5.0% | 27,584 | +14.7% | 0.00% | 0.0% |
| Q3 2018 | $2,056,000 | -58.5% | 24,055 | -43.8% | 0.00% | 0.0% |
| Q2 2018 | $4,956,000 | +142.0% | 42,771 | +69.0% | 0.00% | 0.0% |
| Q1 2018 | $2,048,000 | +49.2% | 25,306 | +8.2% | 0.00% | – |
| Q4 2017 | $1,373,000 | +61.2% | 23,388 | +28.5% | 0.00% | – |
| Q3 2017 | $852,000 | +77.9% | 18,197 | +36.7% | 0.00% | – |
| Q2 2017 | $479,000 | -27.4% | 13,311 | -37.8% | 0.00% | – |
| Q1 2017 | $660,000 | +67.9% | 21,394 | +82.5% | 0.00% | – |
| Q4 2016 | $393,000 | +128.5% | 11,720 | +81.6% | 0.00% | – |
| Q3 2016 | $172,000 | -90.3% | 6,455 | -91.9% | 0.00% | -100.0% |
| Q2 2016 | $1,768,000 | -25.8% | 80,147 | -1.2% | 0.00% | 0.0% |
| Q1 2016 | $2,383,000 | -19.4% | 81,150 | -9.4% | 0.00% | 0.0% |
| Q4 2015 | $2,956,000 | +121.4% | 89,541 | +142.4% | 0.00% | 0.0% |
| Q3 2015 | $1,335,000 | -15.6% | 36,941 | +5.0% | 0.00% | 0.0% |
| Q2 2015 | $1,582,000 | -24.5% | 35,186 | -48.6% | 0.00% | – |
| Q1 2015 | $2,096,000 | -18.8% | 68,446 | +34.9% | 0.00% | -100.0% |
| Q4 2014 | $2,580,000 | +151.0% | 50,724 | +95.3% | 0.00% | – |
| Q3 2014 | $1,028,000 | -10.5% | 25,976 | -2.6% | 0.00% | – |
| Q2 2014 | $1,148,000 | -46.8% | 26,659 | -50.5% | 0.00% | -100.0% |
| Q1 2014 | $2,156,000 | +151.6% | 53,907 | +71.7% | 0.00% | – |
| Q4 2013 | $857,000 | +115.3% | 31,394 | +80.8% | 0.00% | – |
| Q3 2013 | $398,000 | – | 17,368 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 476,042 | $45,472,000 | 12.29% |
| Stonepine Capital Management, LLC | 60,840 | $5,811,000 | 3.34% |
| ACUTA CAPITAL PARTNERS, LLC | 61,000 | $5,827,000 | 2.77% |
| Virtus ETF Advisers LLC | 10,634 | $1,016,000 | 2.16% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 61,000 | $5,827,000 | 2.15% |
| ARMISTICE CAPITAL, LLC | 372,000 | $35,533,000 | 1.94% |
| Matarin Capital Management, LLC | 209,403 | $20,002,000 | 1.46% |
| Monashee Investment Management LLC | 50,000 | $4,776,000 | 1.10% |
| Granahan Investment Management | 151,322 | $14,454,000 | 0.78% |
| ALGERT GLOBAL LLC | 13,186 | $1,260,000 | 0.72% |